ReviewAnnals of gastroenterology
Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges.
Review in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- Prediction of potential NS3-based T cell epitopes of hepatitis C virus by in-silico and in-vitro approach.Scientific reports · 2026Article
- A Systematic Review and Narrative Synthesis of Factors Impacting Late Diagnosis of Chronic Hepatitis B and C.Health science reports · 2026Review
- Prediction of Treatment Response in Hepatitis B and Hepatitis C Coinfected Patients Using a Leakage-Proof, Internally Validated Logistic Regression Pipeline.Advances in virology · 2026Article
- Changes in Bone Microarchitecture and Inflammatory Cytokines After Cure of Chronic Hepatitis C Infection With Direct-Acting Antiviral Therapy.Open forum infectious diseases · 2025Article
- Abnormal Trabecular and Cortical Bone Microarchitecture in Chronic Hepatitis C Infection and Associations With Select Inflammatory Cytokines.Open forum infectious diseases · 2025Article
- Article
- A Machine Learning-Based Mortality Prediction Model for Patients with Chronic Hepatitis C Infection: An Exploratory Study.Journal of clinical medicine · 2024Article
- Hepatitis C Virus Antiviral Drug Resistance and Salvage Therapy Outcomes Across Australia.Open forum infectious diseases · 2024Article
- Association of Blood NK Cell Phenotype with the Severity of Liver Fibrosis in Patients with Chronic Viral Hepatitis C with Genotype 1 or 3.Diagnostics (Basel, Switzerland) · 2024Article
- CDC Recommendations for Hepatitis C Testing Among Perinatally Exposed Infants and Children - United States, 2023.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2023Article
- Effectiveness and Safety of Sofosbuvir-Velpatasvir in Patients with Cirrhosis Associated with Genotype 3 Hepatitis C Infection in Xinjiang, China.Infection and drug resistance · 2022Article
- Benzothiazoles as potential antiviral agents.The Journal of pharmacy and pharmacology · 2020Review
- Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma.BMC cancer · 2019Observational
- High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting.Virology journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) represents a global burden on healthcare that affects over 150 million people worldwide. In the past, HCV genotype 3 was considered difficult to treat relative to other genotypes. Genotype 3 has been associated with a higher rate of complications, including fatty liver disease, fibrosis, hepatocellular carcinoma and mortality. However, with the advent of first- and second-generation direct-acting antivirals, genotype 3 can be treated effectively. Additionally, these new drugs are well tolerated by patients and have significantly fewer side effects compared to ribavirin and interferon-based regimens. However, while great strides have been made in overcoming biological barriers, our next challenge lies in overcoming economic and financial obstacles if we are to eradicate HCV genotype 3. Herein, we review the clinical features associated with HCV genotype 3, current and emerging treatment regimens, and challenges associated with treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.